SeaCrest Wealth Management’s Anixa Biosciences ANIX Stock Holding History

SeaCrest Wealth Management’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-500	Closed	-$1K	–	2189
2017 Q4	$1K	Buy	+500	New	+$1.3K	﹤0.01%	2067

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

DIA

Denver Investment Advisors Denver, Colorado $1.89B AUM 7.9% 1-Year Est. Return

CAM

Concorde Asset Management Ann Arbor, Michigan $204M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SeaCrest Wealth Management's ANIX Position: Q1 2018 in Review

SeaCrest Wealth Management sold out of Anixa Biosciences (ANIX) in Q1 2018, closing a stake of 500 shares — an estimated $1K sold.

SeaCrest Wealth Management first reported a position in ANIX in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 18 funds tracked by Wall St. Rank hold ANIX as of Q1 2018.

SeaCrest Wealth Management reported no remaining Anixa Biosciences position as of Q1 2018 after selling out during the quarter.
SeaCrest Wealth Management sold 500 Anixa Biosciences shares in Q1 2018, an estimated $1K.
SeaCrest Wealth Management first reported a position in Anixa Biosciences in Q4 2017 and held it in 1 quarter.
SeaCrest Wealth Management's Anixa Biosciences position peaked at $1K in Q4 2017.
18 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2018.

Based on SeaCrest Wealth Management's 13F filing for Q1 2018, filed 20 Apr 2018.